Cancer Cell Analysis, Instruments, Consumables and Reagents

Summary Table: Global Market for Cancer Cell Analysis, by Product Type, Through 2023
Table 1: Current Technologies Used in Cancer Cell Analysis
Table 2: Global Prevalence of Cancer, by Type, 2016
Table 3: Major Types of Cancer Prevalence, by Region, 2015 and 2016
Table 4: Investment in Cancer, by Areas of Research
Table 5: Investments in Cancer-Based Research
Table 6: Major Types of Cell-Based Assay Used in HTS for Drug Screening
Table 7: Products in Clinical Development and Regulatory Review, 2016
Table 8: Drugs in Pipeline for Selected Causes, 2017
Table 9: Specific Issues in Personalized Medicine and Cancer
Table 10: In Vivo Versus In Vitro Stem Cell Assays
Table 11: Biomarkers for Cancer Detection, Diagnosis and Prognosis
Table 12: Global Market for Cancer Cell Analysis, by Product Type, Through 2023
Table 13: Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023
Table 14: A Summary of Relevant Single-cell Methods and their Applications to Cancer
Table 15: Global Market for Cancer Cell Analysis, by Consumables, Through 2023
Table 16: Global Market for Consumables in Cancer Cell Analysis, by Region, Through 2023
Table 17: Global Market for Reagents, by Region, Through 2023
Table 18: Kits and Reagents for the Separation of CSCs from Various Starting Materials
Table 19: Kits and Reagents for the Separation of CTCs from Various Starting Materials
Table 20: Global Market for Assay Kits, by Region, Through 2023
Table 21: Determination of Apoptosis and Necrosis in Cancer Cells
Table 22: Summary of Intracellular Metabolic Assays Available to Measure Cellular Proliferation
Table 23: Global Market for Media, by Region, Through 2023
Table 24: The American Cancer Society’s Estimate for Lung Cancer in the United States, 2018
Table 25: Global Market for Microplates, by Region, Through 2023
Table 26: Medicines in Development for Cancer, 2018
Table 27: Global Market for Other Consumables, by Region, Through 2023
Table 28: Global Market for Cancer Cell Analysis, by Instruments, Through 2023
Table 29: Global Market for Cytometers in Cancer Cell Analysis, by Type, Through 2023
Table 30: Global Cytometer Market, by Region, Through 2023
Table 31: Estimated Female Breast Cancer Deaths in the U.S., by Age, 2017
Table 32: Global Spectrophotometers Market, by Region, Through 2023
Table 33: Global Market for Cell Counters in Cancer Cell Analysis, by Type, Through 2023
Table 34: Automatic Cell Counter Technology
Table 35: Comparison Between Manual Cell Counters and Automated Cell Counters
Table 36: Global Market for Cell Counters, by Region, Through 2023
Table 37: Characteristics of Cells
Table 38: Cell Isolation and Separation Techniques
Table 39: Global Market for Cell Isolation and Separation Instruments, by Region, Through 2023
Table 40: Global Market for Microscopes, by Region, Through 2023
Table 41: Global Market for Cell Microarrays, by Region, Through 2023
Table 42: Global Quantitative PCR Market, by Region, Through 2023
Table 43: Global Market for Other Instruments, by Region, Through 2023
Table 44: Global Market for Cancer Cell Analysis, by End User, Through 2023
Table 45: Prevalence of Cancer in Major Countries, by Type, 2015
Table 46: Ongoing Drug Developments and Trials for Cancer
Table 47: Deaths, by Cancer in Major Countries, 2015
Table 48: Global Market for Pharma and Biotech Companies, by Region, Through 2023
Table 49: Technology Approvals and Advancements, by Major Players
Table 50: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
Table 51: Development Works Initiated in CAR T Therapy
Table 52: Global Market for Contract Research Organizations, by Region, Through 2023
Table 53: Market Share of for Drugs Under Development, 2016
Table 54: Some of the Major Collaborations
Table 55: Global Market for Research Organizations and Academic Institutes, by Region, Through 2023
Table 56: International Cancer Research Projects, by Region, 2017-2018
Table 57: Clinical Trials in the Field of Cancer Research
Table 58: Current Grants in the U.S., by Cancer Type, 2018
Table 59: Investment in Cancer Research in Canada, by Cancer Type
Table 60: Global Market for Laboratories and Hospitals, by Region, Through 2023
Table 61: Share of Population with Cancer, by Type, 2016
Table 62: Global Market for Cancer Cell Analysis, by Technique, Through 2023
Table 63: Global Market for Cancer Cell Analysis Techniques, by Region, Through 2023
Table 64: Global Market for Molecular Approach in Cancer Cell Analysis, by Application, Through 2023
Table 65: Global Market for Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023
Table 66: Global Market for PCR in Cancer Cell Analysis, by Region, Through 2023
Table 67: Global Cancer Incidence, by Year, 2005-2016
Table 68: Global Market for Next-Generation Sequencing in Cancer Cell Analysis, by Region, Through 2023
Table 69: NGS Sequencers and Sequencing Technology
Table 70: Various Enrichment Technologies for NGS
Table 71: Quality Control (QC) Metrics for Next-Generation Sequencing
Table 72: Cancer Deaths Worldwide, 2006-2016
Table 73: Global Market for Microfluidics in Cancer Cell Analysis, by Region, Through 2023
Table 74: Size-Based Cancer Cell Separation Microfluidic Devices
Table 75: Microfluidics Devices for Cancer Cell Biophysical Property Characterization
Table 76: Global Market for Other Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023
Table 77: Protein Arrays for the Cancer Biomarker Discovery
Table 78: Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Region, Through 2023
Table 79: Major Growth Drivers for Global Cell Imaging Approach Market
Table 80: Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Application, Through 2023
Table 81: Global Market for FISH in Cancer Cell Analysis, by Region, Through 2023
Table 82: Application of FISH for the Study of Different Cancer Types
Table 83: Global Market for Microscopy in Cancer Cell Analysis, by Region, Through 2023
Table 84: Clinical Trials in Microscopy
Table 85: Global Market for High Content Screening in Cancer Cell Analysis, by Region, Through 2023
Table 86: Initiatives for the Development of Anti-Cancer Drugs, 2016-2018
Table 87: Global Market for Cytometry in Cancer Cell Analysis, by Region, Through 2023
Table 88: Global Deaths Due to Leukemia, 2016
Table 89: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Table 90: Clinical Trials in Cytometry
Table 91: Global Market for Other Cell Imaging Approaches in Cancer Cell Analysis, by Region, Through 2023
Table 92: Global Deaths Due to Breast Cancer, 2012-2016
Table 93: Global Market for Cancer Cell Analysis, by Application, Through 2023
Table 94: Global Market for Cell Imaging Application, by Region, Through 2023
Table 95: Global Market for Cell Imaging in Cancer Cell Analysis, by Region, Through 2023
Table 96: Rising Prevalence of Cancer, by Type, 2005-2015
Table 97: Global Market for Cell Viability and Proliferation in Cancer Cell Analysis, by Region, Through 2023
Table 98: Cell Viability at Various Concentrations of Anti-Cancer Drug
Table 99: Global Market for Cell Signaling Pathways in Cancer Cell Analysis, by Region, Through 2023
Table 100: National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016
Table 101: Global Market for RNA Expression in Cancer Cell Analysis, by Region, Through 2023
Table 102: Ongoing and Completed Clinical Trials on RNA Expression-based Cancer Cell Analysis
Table 103: Biotechnology R&D Expenditures, by Country, 2011 and 2015
Table 104: Key Differences in Normal Cells and Cancer Cells
Table 105: Global Market for Cell Growth and Manipulation in Cancer Cell Analysis, by Region, Through 2023
Table 106: In Vitro and In Vivo Studies Deploying Modified and Altered Exosomes for Effective Cancer Treatment
Table 107: Global Market for Cell Immunotherapy in Cancer Cell Analysis, by Region, Through 2023
Table 108: Global Market for Flow Cytometry in Cancer Cell Analysis, by Region, Through 2023
Table 109: Global Market for Genotypic or Phenotypic Research in Cancer Cell Analysis, by Region, Through 2023
Table 110: Active Clinical Studies Involving Genotypic or Phenotypic Cancer Research, 2015-2018
Table 111: Global Market for Drug Discovery and Development in Cancer Cell Analysis, by Region, Through 2023
Table 112: North American Market for Cancer Cell Analysis, by Country, Through 2023
Table 113: U.S. Cancer Incidence in Males, by Cancer Type, 2017
Table 114: U.S. Cancer Incidence in Females, by Cancer Type, 2017
Table 115: Current Grants, by Cancer Type, 2017
Table 116: Estimates of National Expenditures for Cancer Care, by Cancer Site, 2010-2017
Table 117: Canadian Cancer Incidence in Males, by Cancer Type, 2017
Table 118: Canadian Cancer Incidence in Females, by Cancer Type, 2017
Table 119: Current Cancer Research Funding in Canada, 2018
Table 120: Asia-Pacific Market for Cancer Cell Analysis, by Country, Through 2023
Table 121: Cancer Prevalence Based on Incidence Rates, 2016
Table 122: Clinical Trials for Cancer Cell Analysis
Table 123: Commonly Diagnosed Cancers in Male, by Cancer Type, 2017
Table 124: Commonly Diagnosed Cancers in Female, by Cancer Type, 2017
Table 125: Percentage Change in Cancer Prevalence, 2005-2016
Table 126: Distribution, by Cancer Type, 2015
Table 127: Clinical Trials for Cancer Cell Analysis (Singapore)
Table 128: European Cancer Cell Analysis Market, by Country, Through 2023
Table 129: Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020
Table 130: Site-specific Research Funding in the United Kingdom, 2015
Table 131: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015
Table 132: Ongoing and Completed Clinical Trials on Cancer Cell Analysis in France
Table 133: Estimates of Spain’s Cancer Incidence in Men and Women, by Cancer Type, 2015
Table 134: DFF-Research Projects Grants from the Danish Council for Independent Research to Promote Cancer Cell Analysis in June 2015
Table 135: Projects Recommended to the NCU Board for Funding, 2016
Table 136: ROW Cancer Cell Analysis Market, by Country, Through 2023
Table 137: Brazil’s New Cases of Cancer, by Gender, 2016
Table 138: Clinical Trials in Mexico for Cancer Cell Analysis
Table 139: Leading Causes of Death in Argentina and Percentage Change from 2005 to 2016
Table 140: Kenya’s Prevalence of Cancer, by Cancer Type, 2015 and 2016
Table 141: M&A Deals in Life Science Sector, 2017
Table 142: Investment Analysis
Table 143: U.S. Cancer Cell Analysis Patent, 2018
Table 144: European Cancer Cell Analysis Patents, 2015-2018
Table 145: Japanese Cancer Cell Analysis Patent, 2015-2018
Table 146: Abbott: Product Portfolio
Table 147: Abbott: Recent Developments, 2018
Table 148: ACEA Biosciences Inc.: Product Portfolio
Table 149: ACEA Biosciences Inc.: Recent Developments, 2017 and 2018
Table 150: Agilent Technology Inc.: Product Portfolio
Table 151: Agilent Technology Inc.: Recent Developments, 2015-2017
Table 152: Becton, Dickinson and Co.: Product Portfolio
Table 153: Becton, Dickinson and Co.: Recent Developments, 2015-2018
Table 154: Bio-Rad Laboratories Inc.: Product Portfolio
Table 155: Bio-Rad Laboratories Inc.: Recent Developments, 2016 and 2017
Table 156: Cellix Ltd.: Product Portfolio
Table 157: Cynvenio Biosystems Inc.: Product Portfolio
Table 158: Cynvenio Biosystems Inc.: Recent Developments, 2017 and 2018
Table 159: Danaher Corp.: Product Portfolio
Table 160: Danaher Corp.: Recent Developments, 2016-2018
Table 161: F. Hoffmann-LA Roche AG: Product Portfolio
Table 162: F. Hoffmann-LA Roche AG: Recent Developments, 2015-2017
Table 163: Fluidigm Corp.: Product Portfolio
Table 164: Fluidigm Corp.: Recent Developments, 2018
Table 165: GE Healthcare: Product Portfolio
Table 166: GE Healthcare: Recent Developments, 2017 and 2018
Table 167: GenScript: Product Portfolio
Table 168: Intellicyt Corp.: Product Portfolio
Table 169: Intellicyt Corp.: Recent Developments, 2016-2018
Table 170: Logos Biosystems: Product Portfolio
Table 171: lonza Group Ltd.: Product Portfolio
Table 172: LumaCyte LLC: Product Portfolio
Table 173: LumaCyte LLC: Recent Developments, 2016-2018
Table 174: Merck Millipore: Product Portfolio
Table 175: Merck Millipore: Recent Developments, 2016-2018
Table 176: Olympus Corp.: Product Portfolio
Table 177: Olympus Corp.: Recent Developments, 2015-2018
Table 178: PerkinElmer Inc.: Product Portfolio
Table 179: PerkinElmer Inc.: Recent Developments, 2015-2018
Table 180: Promega Corp.: Product Portfolio
Table 181: QIAGEN Inc.: Product Portfolio
Table 182: QIAGEN Inc.: Recent Developments, 2015-2018
Table 183: Siemens Healthcare GmbH: Product Portfolio
Table 184: Siemens Healthcare GmbH: Recent Developments, 2016-2018
Table 185: Tecan Group Ltd.: Product Portfolio
Table 186: Tecan Group Ltd.: Recent Developments, 2015-2017
Table 187: ThermoFischer Scientific: Product Portfolio
Table 188: ThermoFischer Scientific: Recent Developments, 2017 and 2018
Table 189: Takara Bio: Product Portfolio
Table 190: Takara Bio: Recent Developments, 2017 and 2018

Summary Figure: Global Market for Cancer Cell Analysis, by Product Type, 2017-2023
Figure 1: Applications of Cancer Cell Analysis: A General Overview
Figure 2: Global Prevalence of Cancer, by Type, 2016
Figure 3: The Drug Discovery Process: The Assay Development Stage
Figure 4: Products in Clinical Development and Regulatory Review, 2016
Figure 5: Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023
Figure 6: Five Major Classes in In Vitro-Based Assays
Figure 7: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
Figure 8: Basic Components of a Spectrophotometer
Figure 9: Classification of Cell Microarrays
Figure 10: Key Application of Quantitative PCR or Real-Time PCR
Figure 11: End-User Segmentation
Figure 12: Workflow for Gene Expression
Figure 13: Prevalence of Cancer in Major Countries, by Type, 2015
Figure 14: Deaths, by Cancer in Major Countries, 2015
Figure 15: CAR T Cell Therapy in Immuno-Oncology Medicine Development, 2017
Figure 16: CAR T Cell Therapy Mechanism
Figure 17: Private Risk Sharing Contracts Announced, 1990-2017
Figure 18: Market Share for the Drugs Under Development, 2016
Figure 19: Projects in Development Based on Novel Approaches, by Type, 2016
Figure 20: Primary Growth Drivers
Figure 21: Application of Single-Cell Analysis in Cancer Research
Figure 22: Prevalence of Prostate Cancer in the United States
Figure 23: Share of Population with Cancer, by Type, 2016
Figure 24: Workflow for Laboratories Undertaking Molecular Pathology for Cancer Patients from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Samples
Figure 25: Clinical Use of Molecular Diagnostics
Figure 26: Global Cancer Incidence, by Year, 2005-2016
Figure 27: Cancer Deaths Worldwide, 2006-2016
Figure 28: Subsegments of Cell Imaging Approach
Figure 29: Advantages Offered by Fluorescent In Situ Hybridization
Figure 30: Types of Microscopy Techniques
Figure 31: Advantages Offered by High Content Screening
Figure 32: Global Deaths Due to Leukemia, 2016
Figure 33: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Figure 34: Global Deaths Due to Breast Cancer, 2012-2016
Figure 35: Applications of Cancer Cell Analysis
Figure 36: Types of Cancer Cell Imaging
Figure 37: Workflow for an Imaging-Based Cell Migration Experiment
Figure 38: Cell Viability at Various Concentrations of Anti-Cancer Drug
Figure 39: Mechanism of Cell Signaling
Figure 40: Types of Cell Signaling Pathways
Figure 41: National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016
Figure 42: Techniques of RNA Expression
Figure 43: Biotechnology R&D Expenditures, by Country, 2011 and 2015
Figure 44: Antitumor Impacts of Innate Immune Cells
Figure 45: Integration of Gene Therapy and Stem Cells for Cancer Treatment
Figure 46: Production Process of CAR T Cells
Figure 47: Flow Cytometry Automated Cancer Cell Analysis Pipeline
Figure 48: Application of Single-Cell Sequencing Technology in Tumor Evolution and Metastasis
Figure 49: Major Breakthroughs in Cancer Research in India
Figure 50: Commonly Diagnosed Cancers in Male, by Cancer Type, 2017
Figure 51: Commonly Diagnosed Cancers in Females, by Cancer Type, 2017
Figure 52: Distribution, by Cancer Type, 2015
Figure 53: Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020
Figure 54: Workflow of Anticancer Drug Discovery
Figure 55: Site-specific Research Funding in the United Kingdom, 2015
Figure 56: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015
Figure 57: Estimates of Spain’s Cancer Incidence in Men and Women, by Cancer Type, 2015
Figure 58: Keyna’s Prevalence of Cancer, by Cancer Type, 2015 and 2016
Figure 59: Industry Process Flow within Cancer Cell Analysis Market
Figure 60: Outline of Cancer Cell Analysis Industry
Figure 61: R&D Phase from Conceptualization to Development
Figure 62: Marketing Matrix for Cancer Cell Analysis Products
Figure 63: Factors Influencing Contracts with Suppliers within the Cancer Cell Analysis Market
Figure 64: Factors Driving M&A Deals Across the Life Science Sector
Figure 65: Generalized Manufacturing Process Flow for Cancer Cell Analysis Products
Figure 66: Global Oncology Therapeutic and Care Spending, 2013-2020